araag2/HINT huggingface dataset:
Clinical trial NCT00462748 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: ezetimibe (+) simvastatin, comparator: atorvastatin, comparator: rosuvastatin
SMILES: O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patient Is Male Or Female And Aged Over 18

          -  Patient Provides Written Informed Consent

          -  Patient Has A Fasting Ldl-C Level >2mmol/L At Both Visit 1 And Again At Visit 2

          -  Patient Has Established Cvd, Diabetes Or At "High Risk" Of Cvd (>20 % Risk Over 10
             Years, Framingham Scale)

          -  Patient Has Taken Simvastatin 40mg Continuously For The Past 6 Weeks

          -  Patient Has A Fasting Triglyceride Level Of <3.7mmol/L

          -  Patient Has Hba1c <9% At Visit 1

          -  Patient Is 75% Compliant With Medication Between Visit 1 And Visit 2

        Exclusion Criteria:

          -  Patient Is Hypersensitive To Any Of The Study Medications Or Their Components

          -  Patient Has A History Of, Or Active Liver Disease (Persistent Elevation Of Alt / Ast
             (>3xuln)

          -  Patient Is Pregnant, Lactating, Or A Female Patient Of Childbearing Potential Not
             Using Adequate Contraception

          -  Patient Has Severe Renal Impairment: Creatinine Clearance <30ml/Min (Cockcroft-Gault
             Equation) (In Patients With Moderate Renal Impairment: <60ml/Min, The Dose Of
             Rosuvastatin Will Be 5mg In Line With The Spc)

          -  Patient Has Uncontrolled Endocrine Or Metabolic Disease Known To Influence Serum
             Lipids Or Lipoproteins (I.E. Secondary Causes Of Hyperlipidaemia Such As
             Hypothyroidism Or Hyperthyroidism)

          -  Patient Has A Recent History Of, Or Current, Alcohol Abuse

          -  Patient Has Ck >10 X Uln At Visit 1 Or Visit 2

          -  Patient Has Fasting Ldl-C >4.2mmol/L

          -  Patient Has Any Acute Or Serious Condition, Or History Suggestive Of Myopathy Or
             Predisposing To The Development Of Renal Failure Secondary To Rhabdomyolysis (E.G.
             Sepsis, Hypotension, Major Surgery, Trauma, Severe Metabolic, Severe Endocrine And
             Electrolyte Disorders Or Uncontrolled Seizures)
Clinical trial NCT01009086 (phase 3, status: completed)
Conditions: arthritis, psoriatic
ICD codes: L40.52
Drugs: placebo, ustekinumab 45 mg, ustekinumab 90 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have had a documented diagnosis of psoriatic arthritis (PsA) at least 6 months

          -  Have a diagnosis of active PsA at the time of entry into the study

          -  If the participant is using methotrexate they should have started treatment at a dose
             not to exceed 25 milligram per week at least 3 months prior to the beginning of the
             study and should have no serious toxic side effects attributable to methotrexate.
             Methotrexate route of administration and doses should be stable for at least 4 weeks
             prior to the first administration of study agent. If currently not using methotrexate,
             must have not received methotrexate for at least 4 weeks prior to the first
             administration of the study agent

        Exclusion Criteria:

          -  Have other inflammatory diseases, including but not limited to rheumatoid arthritis,
             ankylosing spondylitis, systemic lupus erythematosus, or Lyme disease

          -  Have used any therapeutic agent targeted at reducing interleukin (IL)-12 or IL-23,
             including but not limited to ustekinumab and briakinumab (ABT-874)

          -  Have used any biologic agents that are targeted for reducing tumor necrosis
             factor-alpha, including but not limited to infliximab, etanercept, adalimumab, and
             golimumab

          -  Have a medical history of latent or active granulomatous infection

          -  Have any known malignancy or have a history of malignancy (with the exception of basal
             cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in
             situ that has been treated with no evidence of recurrence, or squamous cell carcinoma
             of the skin that has been treated with no evidence of recurrence within 5 years of the
             beginning of the study
Clinical trial NCT00191737 (phase 3, status: completed)
Conditions: attention deficit hyperactivity disorder
ICD codes: F90.2, F90.8, F90.9, F90.0, F90.1
Drugs: atomoxetine
SMILES: CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients who are at least 12 years of age and who will not have
             reached their 18th birthday

          -  Diagnosis of ADHD

          -  Normal intelligence

        Exclusion Criteria:

          -  Weigh less than 30 kg or more than 85 kg at study entry

          -  Other relevant psychiatric diagnoses

          -  Are at serious suicidal risk as determined by the investigator

          -  Have a history of severe allergies

          -  Alcohol or drug abuse within the past 3 months

          -  Are female patients who are pregnant or breast-feeding. Sexually active females must
             use a medically acceptable method of contraception.
Clinical trial NCT00189241 (phase 3, status: completed)
Conditions: basal cell carcinoma
ICD codes: C44.510, C44.91, C44.01, C44.311, C44.511, C44.81, C44.41
Drugs: imiquimod
SMILES: CC(C)CN1C=NC2=C1C1=CC=CC=C1N=C2N
Eligibility criteria:

        Inclusion Criteria:

          -  Have one superficial BCC - primary tumour

          -  Minimum tumour area of 0.5cm2, maximum diameter of 2.0cm.

          -  If female and of child bearing potential, negative pregnancy test and willing to use
             medically acceptable method of contraception.

        Exclusion Criteria:

          -  Evidence of clinically significant, unstable medical conditions.

          -  Evidence of Gorlin syndrome, metastatic tumour or tumour with high probability of
             metastatic spread, have or have had within last 5 years other malignant cancers of the
             skin at target tumour site.

          -  Have received defined treatments in tumour site or surrounding area.

          -  Any dermatological disease in the target tumour site or surrounding area.

          -  Have had a systemic bacterial or viral infection within 2 weeks prior to study
             initiation.
Clinical trial NCT01502241 (phase 3, status: completed)
Conditions: glioblastoma, anaplastic astrocytoma
ICD codes: C84.67, C84.77, C84.7A, C84.60, C84.70, C84.62, C84.66
Drugs: temozolomide
SMILES: CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed supratentorial anaplastic astrocytoma or glioblastoma

          -  Age > 65

          -  Karnofsky performance score > 60%

          -  Neutrophilic granulocyte count > 1500/µl

          -  Platelet count > 100 000/µl

          -  Hemoglobin > 10 g/dl

          -  Serum creatinine < 1.5 times the lab's upper normal limit

          -  AST or ALT < 3 times the lab's upper normal limit

          -  Alkaline phosphatase < 3 times the lab's upper normal limit

          -  No previous systemic chemotherapy

          -  No previous radiotherapy to the brain

          -  Written consent

        Exclusion Criteria:

          -  Serious medical or neurological condition with a poor prognosis

          -  HIV infection

          -  Second cancer requiring radiotherapy or chemotherapy (contact the study coordinat if
             necessary)

          -  Hypersensitivity to temozolomide

          -  Conditions associated with regular vomiting that might affect oral administration of
             the drugs

          -  Psychological, familial, social or geographical circumstances with major implications
             for compliance with the study visit schedule

          -  Patient was taking part in other intervention studies within a month of starting this
             study
Clinical trial NCT00552565 (phase 3, status: completed)
Conditions: irritable bowel syndrome with diarrhea
ICD codes: K58.0, K58.9
Drugs: rezular 15mg, placebo, rezular, rezular
SMILES: COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC, COC1=CC=C(CCNCCC[C@@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)C=C1OC
Eligibility criteria:

        Inclusion Criteria:

          -  fulfilling Rome III criteria for IBS-D

        Exclusion Criteria:

          -  major cardiovascular disease

          -  psychiatric illness except mild or moderate depression

          -  pregnancy

          -  presence of other GI disease that could explain IBS-like symptoms

          -  history of major gastric, hepatic, pancreatic or intestinal surgery or perforation
Clinical trial NCT00589693 (phase 3, status: terminated)
Conditions: ventilator-associated pneumonia
ICD codes: J95.851
Drugs: doripenem, imipenem-cilastatin, placebo
SMILES: [H][C@]12[C@@H](C)C(S[C@]3([H])CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O, CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    observed lower cure rates and higher mortality rates in one of the treatment groups.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have new or worsening radiographic infiltrates consistent with
             ventilator-associated pneumonia that was not related to cardiac or other disease
             processes

          -  Have at least 1 of the following: fever (core body temperature greater than 39.0°C);
             hypothermia (core body temperature of less than 35.0°C); leukocytosis (increased WBC
             count); and leukopenia (decreased WBC count)

          -  Have developed ventilator-associated pneumonia and have been on mechanical ventilation
             for more than or equal to 48 hours and on mechanical ventilation at the time that
             study medication is assigned

          -  Have been hospitalized or been in a chronic care facility for consecutive 5 days or
             more within the last 90 days

          -  Have a baseline Clinical Pulmonary Infection Score (CPIS) more than or equal to 6 and
             an Acute Physiology and Chronic Health Evaluation (APACHE) II score more than 8 and
             less than 35

        Exclusion Criteria:

          -  Have received antibiotics for this episode of ventilator-associated pneumonia for more
             than 24 hours before study medication administration

          -  Known presence at baseline of only methicillin-resistant Staphylococcus aureus or
             Stenotrophomonas infection

          -  Acute respiratory distress syndrome

          -  Has any of the following conditions: chest trauma with severe lung bruising or loss of
             stability of the thoracic cage following a fracture of the sternum, ribs, or both,
             increased amounts of fluid in the lung cavities requiring drainage or pus in the
             cavity

          -  Has active seizure disorder within the last 2 years or brain injury such that imipenem
             cilastatin would not be administered to the patient in usual practice

          -  Has lung cancer within the last 2 years, chronic bronchitis with an increase in
             severity within the last 30 days, chronic enlargement of the bronchi or bronchioles
             related to inflammatory disease or obstruction, lung abscess(s), anatomical bronchial
             obstruction, respiratory tuberculosis on treatment, suspected atypical pneumonia,
             chemical pneumonitis, cystic fibrosis, congestive heart failure, severe burns to
             greater than 15% of the body, evidence of severe and chronic liver disease
Clinical trial NCT02449044 (phase 3, status: completed)
Conditions: hyponatremia
ICD codes: P74.22, E87.1
Drugs: tolvaptan
SMILES: CC1=CC=CC=C1C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCC[C@@H](O)C2=C1C=CC(Cl)=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Age greater than or equal to 18 years.

          2. Ability to provide informed consent or assent.

          3. Prior successful participation in a tolvaptan hyponatremia trial termination with
             evidence of continued need or desire for therapy.

        Exclusion Criteria:

          -  A current medical condition where long-term treatment with an aquaretic agent may
             present an undue risk to the patient.

          -  Hyponatremia which is acute, reversible, artifactual or due to conditions not
             associated with vasopressin excess or likely to respond to aquaretic therapy.

          -  Hyponatremia due to reversible medical condition or therapy

          -  Conditions associated with an independent imminent risk of morbidity and mortality

          -  Conditions which confound the assessment of endpoints.
Clinical trial NCT00332488 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: technosphere insulin, metformin & secretagogues, technosphere insulin & metformin
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, CN(C)C(=N)NC(N)=N, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Non-smokers with clinical diagnosis of Type 2 diabetes mellitus for >or= to 6 months

          -  Stable regimen of metformin for > or = to 1000mg/day or maximum tolerated dose) and a
             secretagogue < or = 1/2 the maximum manufacturer-recommended daily dose without any
             dose adjustments within the preceding 6 wks.

          -  Fixed dose combination products of metformin and sulfonylurea are acceptable as long
             as each individual dose meets inclusion criteria

          -  HbA1c >or= to 7.5% and < or= to 11.0%

          -  BMI < or = to 40kg/m2.

          -  FEV1> or = to 70%, Total Lung capacity and > or =80% DLco > or= to 70%

        Exclusion Criteria:

          -  Treatment with any type of anti-diabetic therapy, other than metformin & secretagogues
             within the preceding 12 weeks

          -  Serum creatinine > 1.4mg/dL in female subjects and >1.5mg/dL in male subjects

          -  History of chronic obstructive pulmonary disease, clinically proven asthma and/or any
             other clinically important pulmonary function testing and/or radiologic findings

          -  Evidence of serious complications of diabetes (e.g. autonomic neuropathy)
Clinical trial NCT00190788 (phase 3, status: completed)
Conditions: sepsis, hypotension
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7, I95.0, I95.1, I95.81, I95.89, I95.9, G96.810, G96.811
Drugs: drotrecogin alfa (activated), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Severe sepsis patients treated with 96 hour infusion of commercial Drotrecogin Alfa
             (Activated)

          -  Continue requirement of Vasopressor support after 96 hour commercial infusion

        Exclusion Criteria:

          -  Patients require extensive surgical procedures within next 3 days

          -  Patients with platelet count below 30,000/mm3

          -  Patients receiving therapeutic heparin of 15,000 units/day and more

          -  Patients not expected to survive 24 days

          -  Patients contraindicated as to the country specific registration
Clinical trial NCT00607152 (phase 3, status: terminated)
Conditions: hyperuricemia
ICD codes: E79.0
Drugs: rasburicase, allopurinol
SMILES: O=C1N=CN=C2NNC=C12
Reason stopped: 
    the patient enrollment is too difficult
  
Eligibility criteria:

        Inclusion Criteria:

          -  At high risk of malignancy and/or chemotherapy-induced hyperuricemia

          -  Performance status less than 3 on ECOG scale or more than 30% KPS scale

          -  Uric acid concentrations ≥ 8.0mg/dL

          -  Suffering from non-Hodgkin's lymphoma Stage more than III, or acute lymphoblastic
             leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma
             or leukemia

        Exclusion Criteria:

          -  Treatment with an investigational drug at any time during the 14-day study period
             (except for agents that are permitted by the Sponsor)

          -  Pregnancy or lactation

          -  Prior treatment with Uricozyme or Rasburicase

          -  Scheduled to receive asparaginase either 24 hours after the first dose of rasburicase

          -  Treatment with Allopurinol within the seven days preceding study Day 1

          -  History of significant atopic allergy problems or documented history of asthma

          -  History of severe reaction to allopurinol

          -  Known history of glucose-6-phosphate dehydrogenase deficiency.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00556712 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib [tarceva], placebo
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  histologically documented, locally advanced , recurrent or metastatic NSCLC;

          -  measurable disease;

          -  no disease progression after 4 cycles of platinum-based chemotherapy.

        Exclusion Criteria:

          -  unstable systemic disease;

          -  any other malignancies in the last 5 years.
Clinical trial NCT00460265 (phase 3, status: completed)
Conditions: recurrent and/or metastatic head and neck cancer
ICD codes: C67.5, C76.0, C44.40, D23.4, C44.49, C47.0, C49.0
Drugs: arm 2, arm 1
SMILES: CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1, CC(C)C1=CC=CC(C(C)C)=C1OCOP(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Man or woman at least 18 years old.

          -  Histologically or cytologically confirmed metastatic and/or recurrent squamous cell
             carcinoma (or its variants) of the head and neck.

          -  Diagnosis of metastatic disease and/or recurrent disease following locoregional
             therapy and determined to be incurable by surgery or radiotherapy.

          -  Subjects who have received radiation as primary therapy are eligible if locoregional
             recurrence is in the field of radiation and has occurred ≥6 months after the
             completion of radiation therapy. Subjects whose locoregional recurrence is solely
             outside the field of radiation are eligible if the recurrence has occurred ≥ 3 months
             after the completion of radiation therapy.

          -  Measurable and non-measurable disease.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

        Exclusion Criteria:

          -  History or known presence of Central Nervous System (CNS) metastases.

          -  History of another primary cancer, except: curatively treated in situ cervical cancer,
             or curatively resected non-melanoma skin cancer, or other primary solid tumor
             curatively treated with no known active disease present and no treatment administered
             for ≥ 2 years before randomization.

          -  Nasopharyngeal carcinoma.

          -  Prior systemic treatment for metastatic and/or recurrent SCCHN

          -  Prior cisplatin containing induction chemotherapy followed by cisplatin containing
             chemoradiotherapy

          -  Prior anti-EGFr (Epidermal growth factor receptor) antibody therapy or treatment with
             small molecule EGFr inhibitors

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) less than or equal to 1 year prior to randomization. History of
             interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of
             interstitial lung disease on baseline chest computerized tomography (CT) scan.

          -  Symptomatic peripheral neuropathy grade ≥ 2 based on the CTCAE v3.0

          -  Grade ≥ 3 hearing loss based on the Common Terminology Criteria for Adverse Events
             (CTCAE) v3.0 Auditory/Ear (Hearing [without monitoring program])
Clinical trial NCT00235716 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: dl-alpha-tocopherol, memantine, dl-alpha-tocopherol, memantine, placebo
SMILES: CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1, CC12CC3CC(C)(C1)CC(N)(C3)C2, CC(C)CCCC(C)CCCC(C)CCCC1(C)CCC2=C(C)C(O)=C(C)C(C)=C2O1, CC12CC3CC(C)(C1)CC(N)(C3)C2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnoses of possible or probable Alzheimer's disease (NINCDS-ADRDA)

          2. Presence of a caregiver (friend or relative) who can assume responsibility for
             medication compliance, can accompany the patient to all visits, and rate patient's
             condition

          3. Written informed consent from both the patient (or surrogate) and caregiver

          4. An MMSE score between 12 and 26 inclusive

          5. Administration of a maintenance dosage of donepezil (5-10mg/d), rivastigmine
             (6-12mg/d) or rivastigmine (Exelon) patch (4.6 mg or 9.5 mg), galantamine or
             galantamine ER (16-24mg/d) for a minimum of 4 weeks prior to randomization

          6. Agreement not to take vitamin E supplements and/or memantine outside of the study
             (daily multivitamin is permitted containing up to 100 IU alpha-tocopherol)

        Exclusion Criteria:

          1. A non-Alzheimer primary dementia (e.g., vascular dementia, Lewy body dementia,
             fronto-temporal dementia, vitamin B-12 deficiency, hypothyroidism)

          2. Current major depression, delirium, alcohol or psychoactive substance abuse or
             dependency, schizophrenia, or delusional disorder as defined by DSM-IV

          3. Presence of any uncontrolled systemic illness that would interfere with participation
             in the study or a life expectancy of less than one year

          4. Pregnant or intention to become pregnant

          5. Enrollment in another interventional clinical trial

          6. Current prescription with more than one AChE inhibitor

          7. Current prescription for warfarin

          8. Use of vitamin E supplements in the past 2 weeks

          9. Use of memantine in the past 4 weeks or known intolerance

         10. Estimated creatinine clearance less than 5ml/min (Cockcroft-Gault formula)

         11. Use of amantadine in the past 2 weeks